Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cy - Erie News Now | WICU & WSEE in Erie, PA

Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact


NEW YORK, October 3, 2017 /PRNewswire/ --

If you want a Stock Review on CBAY, CYTX, CYTR, or SRNE then come over to and sign up for your free customized report. On Monday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.32%; the Dow Jones Industrial Average edged 0.68% higher; and the S&P 500 was up 0.39%. US markets made broad based gains with eight out of nine sectors finishing the day in green. Pre-market today, reviews these four Biotechnology stocks: Cymabay Therapeutics Inc. (NASDAQ: CBAY), Cytori Therapeutics Inc. (NASDAQ: CYTX), CytRx Corp. (NASDAQ: CYTR), and Sorrento Therapeutics Inc. (NASDAQ: SRNE). Access's free research reports for this morning's stocks line-up at:

Cymabay Therapeutics 

Newark, California headquartered Cymabay Therapeutics Inc.'s stock finished Monday's session 4.47% lower at $7.70. A total volume of 654,684 shares was traded. The Company's shares have advanced 23.40% in the past month, 30.73% over the previous three months, 296.91% in the last twelve months, and 345.09% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.82% and 72.37%, respectively. Furthermore, shares of Cymabay Therapeutics, which focuses on developing and commercializing therapies to treat specialty and orphan diseases, have a Relative Strength Index (RSI) of 56.89. Free research report on CBAY is available at:

Cytori Therapeutics 

Shares in San Diego, California headquartered Cytori Therapeutics Inc. ended at $0.36, down 2.26% from the last trading session. The stock recorded a trading volume of 349,641 shares. The stock is trading below its 50-day moving average by 6.63%. Moreover, shares of Cytori Therapeutics, which develops cellular therapeutics for specific diseases and medical conditions, have an RSI of 48.15.The complimentary research report on CYTX can be downloaded at:


Los Angeles, California headquartered CytRx Corp.'s stock ended yesterday's session 2.15% higher at $0.42 with a total trading volume of 1.06 million shares. The Company's shares have advanced 12.52% on an YTD basis. The stock is trading below its 50-day moving average by 24.27%. Additionally, shares of CytRx, which operates as a biopharmaceutical research and development company specializing in oncology, have an RSI of 34.41. Visit us today and access our complete research report on CYTR at:

Sorrento Therapeutics 

On Monday, shares in San Diego, California-based Sorrento Therapeutics Inc. recorded a trading volume of 568,433 shares, which was above their three months average volume of 537.41 thousand shares. The stock finished the day 2.94% higher at $1.75. The stock is trading below its 50-day moving average by 2.97%. Furthermore, shares of Sorrento Therapeutics, which engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide, have an RSI of 49.93. Get free access to your research report on SRNE at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly
3514 State St. Erie, PA 16508
Newsroom: (814) 454-8812
Business offices: (814) 454-5201
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
RSS Feeds
All content © Copyright 2000 - 2017 WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 -